| Literature DB >> 16399645 |
Harun Akar1, David C Seldin, Barbarajean Magnani, Carl O'Hara, John L Berk, Christopher Schoonmaker, Howard Cabral, Laura M Dember, Vaishali Sanchorawala, Lawreen H Connors, Rodney H Falk, Martha Skinner.
Abstract
We compared a new serum immunoassay for quantitation of serum free light chains (FLC) with the conventional tests for clonal immunoglobulin production: bone marrow immunohistochemistry, serum immunofixation electrophoresis, and urine immunofixation electrophoresis. Serum samples from 169 patients with AL amyloidosis and 20 controls were examined. Elevated levels of kappa-FLC and lambda-FLC were found in 94% and 93% of patients with the respective clonal disease. However, false positive elevations of kappa-FLC and lambda-FLC were found in 30% and 44% of patients with clonal disease of the other light chain subtype. We found that the FLC level was a reliable test for the diagnosis of clonal disease when the FLC kappa:lambda ratio was abnormal and was comparable to the conventional tests in patients with AL amyloidosis. After a histologic tissue diagnosis of amyloidosis, determining the type as AL amyloidosis relies on a panel of hematologic tests to determine light chain clonality and the exclusion other forms of amyloidosis.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16399645 DOI： 10.1080/13506120500352339
Source DB: PubMed Journal: Amyloid ISSN： 1350-6129 Impact factor: 7.141